RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación
Artículo científico (JournalArticle)
Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma
[EN] Background Tobacco is the main risk factor for developing lung cancer. Yet, while some heavy smokers develop lung cancer at a young age, other heavy smokers never develop it, even at an advanced age, suggesting a remarkable variability in the individual susceptibility to the carcinogenic effects of tobacco. We characterized the germline pro fi le of subjects presenting these extreme phenotypes with Whole Exome Sequencing (WES) and Machine Learning (ML). Methods We sequenced germline DNA from heavy smokers who either developed lung adenocarcinoma at an early age ( extreme cases ) or who did not develop lung cancer at an advanced age ( extreme controls ), selected from databases including over 6600 subjects. We selected individual coding genetic variants and variant -rich genes showing a signi fi cantly different distribution between extreme cases and controls. We validated the results from our discovery cohort, in which we analysed by WES extreme cases and controls presenting similar phenotypes. We developed ML models using both cohorts. Findings Mean age for extreme cases and controls was 50.7 and 79.1 years respectively, and mean tobacco consumption was 34.6 and 62.3 pack -years. We validated 16 individual variants and 33 variant -rich genes. The gene harbouring the most validated variants was HLA-A in extreme controls (4 variants in the discovery cohort, p = 3.46E-07; and 4 in the validation cohort, p = 1.67E-06). We trained ML models using as input the 16 individual variants in the discovery cohort and tested them on the validation cohort, obtaining an accuracy of 76.5% and an AUC-ROC of 83.6%. Functions of validated genes included candidate oncogenes, tumoursuppressors, DNA repair, HLA-mediated antigen presentation and regulation of proliferation, apoptosis, in fl ammation and immune response. Interpretation Individuals presenting extreme phenotypes of high and low risk of developing tobacco -associated lung adenocarcinoma show different germline pro fi les. Our strategy may allow the identi fi cation of high -risk subjects and the development of new therapeutic approaches., We particularly acknowledge our patients for their participation and the Biobank of the University of Navarra and Hospital General of Valencia for their collaboration. We are thankful to Dr. Paul Miller, University of Navarra, for English editing of the manuscript and to Pablo Esquiroz for fi gure editing. This work was funded by the Spanish Society of Medical Oncology, Fundacion SEOM and Fundacion Salud 2000 and by an unrestricted grant from Roche. CC and EJ work is supported by the Spanish Health Institute Carlos III (ISCII, Fondo de Investigacion Sanitaria: CB16/12/00350) . ME has received funding from the European Research Council (ERC) under Horizon 2020 research and innovation programme (Onco-Energetics_OFF, Grant agreement No. 852761) and the DFG (German Research Foundation) Project No. EL 1081/2-1. RP work is supported by the Spanish Health Institute Carlos III (ISCII, Fondo de Investigacion Sanitaria: PI20/12/00419) . This work was supported by FIMA, CIBERONC (CB16/12/00443) , Spanish Ministry of Economy and Innovation and Fondo de Investigacion Sanitaria Fondo Europeo de Desarrollo Regional (PI22/00451; to L.M. Montuenga) and Lung Ambition Alliance grant (to Luis M. Montuenga) . IO declares declares research grants and support from a Ramon y Cajal contract RYC2019-028578-I, a Gipuzkoa Fellows grant 2022-FELL-000003-01, and grant PID2021-126718OA-I00 funded by MCIN/AEI/10.13039/501100011033. MH declares research grants and support from MCIN/AEI/10.13039/501100011033 [grant number PID2020-114394RA-C33] and Ramon y Cajal contract RYC2021-033127-I.
Proyecto:
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-114394RA-C33
,
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-126718OA-I00
,
European Commission / H2020 852761
,
Instituto de Salud Carlos III / Plan Estatal de Investigación Científica PI22/00451
,
Ministerio de Economía y Competitividad / Técnica y de Innovación 2021-2023 CB16/12/00350
,
Ministerio de Economía y Competitividad CB16/12/00443
,
Instituto de Salud Carlos III PI20/12/00419
,
Ministerio de Ciencia RYC2021-033127-I
,
Innovación y Universidades RYC2019-028578-I